EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Lactoferrin-Modified Ultra-Sustained Release Propofol Nanoparticles for Multi-Pathway Therapy of Depression via Intraperitoneal Injection

Zhenyi Wu, Junze Deng, Shunlian Li, Lu Yu iD, Hang Zhang, Yufeng Xun iD, Jing Bian, Jing Liu, Jianbo Zhang, Pu Lei, Qingyan Ma, Yajuan Fan und 5 weitere

International Journal of Nanomedicine · 2026

DOI: 10.2147/ijn.s645818 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Nanomedicine, 2026. Verfasst von Zhenyi Wu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Center for Brain Science, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic …. Hauptthemen laut MEDLINE: Propofol, Depression, Nanoparticles, Lactoferrin. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Depression imposes a significant burden on global public health, and traditional antidepressants are limited by slow onset, low efficacy, and high recurrence rates. Intraperitoneal injection of propofol can rapidly exert anti-anhedonic effects by regulating the VTA-NAc dopaminergic and GABAergic signaling pathways. However, its application in depression treatment is limited by rapid systemic clearance, poor brain permeability, and significant systemic toxicity. Moreover, the simple lipophilic structure of propofol and the limited drug-loading and long-term controlled-release performance of conventional physically encapsulated nanocarriers hinder the development of long-acting propofol formulations.

Methods

Lactoferrin-functionalized PVA-propofol nanoparticles (LF-PVA@Pro NPs) were prepared based on the strong intermolecular affinity between PVA and propofol, as validated by molecular dynamics simulations. Their physicochemical properties, in vitro release behavior, brain-targeting efficiency, biosafety, and in vivo antidepressant efficacy were systematically characterized using CRS-induced depressive mouse models through multiple behavioral and histological assessments.

Results

LF-PVA@Pro NPs achieved a drug loading of 19.3% and exhibited sustained in vitro release for 100 h. Following intraperitoneal injection, the formulation maintained therapeutic brain concentrations for 100 h (6-8-fold longer than free propofol) and increased cerebral drug accumulation by 2.5-fold. Its LD50 was 2802 mg/kg, 2.36-fold higher than that of free propofol, ensuring safety at the therapeutic dose of 40 mg/kg. In vivo studies demonstrated that LF-PVA@Pro NPs markedly alleviated depressive- and anxiety-like phenotypes, reduced VTA/NAc neuronal injury, and restored c-Fos, GABA, and DAT expression, thereby reactivating reward circuits.

Conclusion

LF-modified ultra-sustained brain-targeted nanoparticles enable multi-pathway long-term depression intervention, offering a translatable strategy to repurpose propofol as a rapid-onset antidepressant for chronic stress-related depression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PropofolDepressionNanoparticlesLactoferrinAntidepressive AgentsAnimalsMiceDelayed-Action PreparationsInjections, IntraperitonealMaleBrain

Stichwörter der Autor:innen

depressionmolecular dynamics simulationsmulti-pathway therapypropofol nanoparticlesultra-sustained release

Substanzen

PropofolDelayed-Action PreparationsLactoferrinAntidepressive Agents

Autor:innen und Institutionen

  • Department of Psychiatry and Center for Brain Science, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.
  • Yan'an Medical College of Yan'an University, Yan'an, Shaanxi, People's Republic of China.
  • Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, People's Republic of China.
  • Center for Translational Medicine, The First Affiliated Hospital of Xi' an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.
  • College of Forensic Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.
  • Key Laboratory of Biomedical Information Engineering of the Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.

ORCID-Profile: Lu Yu, Yufeng Xun, Xiancang Ma, Daocheng Wu

Zitieren

APA

Wu, Z., Deng, J., Li, S., Yu, L., Zhang, H., Xun, Y., Bian, J., Liu, J., Zhang, J., Lei, P., Ma, Q., Fan, Y., Yang, Z., Zhu, F., Ma, X., Wu, D., & Zhang, S. (2026). Lactoferrin-Modified Ultra-Sustained Release Propofol Nanoparticles for Multi-Pathway Therapy of Depression via Intraperitoneal Injection. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s645818

Vancouver

Wu Z, Deng J, Li S, Yu L, Zhang H, Xun Y, et al. Lactoferrin-Modified Ultra-Sustained Release Propofol Nanoparticles for Multi-Pathway Therapy of Depression via Intraperitoneal Injection. International Journal of Nanomedicine. 2026. doi:10.2147/ijn.s645818

BibTeX
@article{Wu2026,
  author = {Wu, Zhenyi and Deng, Junze and Li, Shunlian and Yu, Lu and Zhang, Hang and Xun, Yufeng and Bian, Jing and Liu, Jing and Zhang, Jianbo and Lei, Pu and Ma, Qingyan and Fan, Yajuan and Yang, Zai and Zhu, Feng and Ma, Xiancang and Wu, Daocheng and Zhang, Shuo},
  title = {Lactoferrin-Modified Ultra-Sustained Release Propofol Nanoparticles for Multi-Pathway Therapy of Depression via Intraperitoneal Injection},
  journal = {International Journal of Nanomedicine},
  year = {2026},
  doi = {10.2147/ijn.s645818}
}
Kostenlos starten →